LONDON: Oncimmune Holdings plc has signed a commercial agreement with Cedars-Sinai, California, USA, to provide antibody profiling in COVID-19 samples as biomarkers for this disease, a news release said. Oncimmune Holdings is being funded by the UK Government to develop a COVID-19 biomarker panel. Cedars-Sinai is a world-leading medical research organisation serving more than 1…